|

Rare and Atypical Diabetes Network

RECRUITINGSponsored by University of South Florida
Actively Recruiting
SponsorUniversity of South Florida
Started2020-09-30
Est. completion2030-09
Eligibility
Healthy vol.Accepted
Locations13 sites

Summary

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

The following criteria or phenotypes will be considered for suspecting "atypical" participants:

* Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
* Mendelian pattern, especially with early onset (\<18 years old)
* Syndromic (multiple systems involved)
* Lipodystrophic
* Extremes of BMI
* "Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
* Non-progressive
* Rapidly progressive ("fulminant")
* Low insulin requirements (\<0.5 u/kg/day)
* Cyclical hyperglycemia with periods of remission
* Lean persons with polycystic ovarian syndrome (PCOS)
* History of gestational diabetes (GDM) when lean
* Lean insulin-resistant persons
* If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function):

oA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)

Exclusion Criteria:

* Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
* Refusal of consent for genetic testing
* Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
* Women who are currently pregnant

Conditions8

DiabetesDiabetes MellitusDiabetes Mellitus ProgressionEndocrine System DiseasesEndocrine; ComplicationsGlucose IntoleranceGlucose Metabolism DisordersMetabolic Disease

Locations13 sites

University of Colorado- Denver
Aurora, Colorado, 80045
Marjan Rezaei303-724-1290marjan.rezaei@cuanschutz.edu
University of Chicago
Chicago, Illinois, 60637
Lisa Letourneau773-702-0829radiant@uchicago.edu
Indiana University
Indianapolis, Indiana, 46202
Sarah Fischer317-278-7042hollowas@iu.edu
University of Maryland
Baltimore, Maryland, 21201
Cindi Young410-979-4322cyoung2@som.umaryland.edu
Massachusetts General Hospital (MGH)
Boston, Massachusetts, 02114
Julia Douvas617-724-3954MGHRADIANTStudy@partners.org

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.